These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 16816548)

  • 21. Lost in translation: preclinical studies on 3,4-methylenedioxymethamphetamine provide information on mechanisms of action, but do not allow accurate prediction of adverse events in humans.
    Green AR; King MV; Shortall SE; Fone KC
    Br J Pharmacol; 2012 Jul; 166(5):1523-36. PubMed ID: 22188379
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Memory performance in polyvalent MDMA (ecstasy) users who continue or discontinue MDMA use.
    Gouzoulis-Mayfrank E; Fischermann T; Rezk M; Thimm B; Hensen G; Daumann J
    Drug Alcohol Depend; 2005 Jun; 78(3):317-23. PubMed ID: 15893163
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Full recovery after severe serotonin syndrome, severe rhabdomyolysis, multi-organ failure and disseminated intravascular coagulopathy from MDMA.
    Davies O; Batajoo-Shrestha B; Sosa-Popoteur J; Olibrice M
    Heart Lung; 2014; 43(2):117-9. PubMed ID: 24373952
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ecstasy: as harmful as heroin?
    Scott R
    J Law Med; 2009 Dec; 17(3):327-48. PubMed ID: 20169795
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Abuse of Ecstasy (3,4-methylenedioxymethamphetamine). Pharmacological, neuropsychiatric and behavioral aspects].
    Nielsen JC; Nicholson K; Pitzner-Jørgensen BL; Undén M
    Ugeskr Laeger; 1995 Feb; 157(6):724-7. PubMed ID: 7701630
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Persisting and late onset psychotic disorder due to consumption of ecstasy (MDMA)].
    Boné Pina I; Ramos Gorostiza P; Villalba Yllán P; Valle Fernández J
    Actas Esp Psiquiatr; 2000; 28(1):61-5. PubMed ID: 10758429
    [TBL] [Abstract][Full Text] [Related]  

  • 27. MDMA-Associated Liver Toxicity: Pathophysiology, Management, and Current State of Knowledge.
    Cajanding RJM
    AACN Adv Crit Care; 2019; 30(3):232-248. PubMed ID: 31462520
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ecstasy (MDMA) and oral health.
    Brand HS; Dun SN; Nieuw Amerongen AV
    Br Dent J; 2008 Jan; 204(2):77-81. PubMed ID: 18268544
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Ecstasy--the status in French-speaking Switzerland. Composition of seized drugs, analysis of biological specimens and short review of its pharmacological action and toxicity].
    Giroud C; Augsburger M; Sadeghipour F; Varesio E; Veuthey JL; Rivier L
    Praxis (Bern 1994); 1997 Mar; 86(13):510-23. PubMed ID: 9157497
    [TBL] [Abstract][Full Text] [Related]  

  • 30. MDMA Induced Cardio-toxicity and Pathological Myocardial Effects: A Systematic Review of Experimental Data and Autopsy Findings.
    Bonsignore A; Barranco R; Morando A; Fraternali Orcioni G; Ventura F
    Cardiovasc Toxicol; 2019 Dec; 19(6):493-499. PubMed ID: 31073690
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Adverse symptomatology and suicide associated with the use of methylenedioxymethamphetamine (MDMA; "Ecstasy").
    Cohen RS
    Biol Psychiatry; 1996 May; 39(9):819-20. PubMed ID: 8731525
    [No Abstract]   [Full Text] [Related]  

  • 32. Ecstasy (3,4-methylenedioxymethamphetamine)-induced inappropriate antidiuretic hormone secretion.
    Farah R; Farah R
    Pediatr Emerg Care; 2008 Sep; 24(9):615-7. PubMed ID: 18797371
    [TBL] [Abstract][Full Text] [Related]  

  • 33. 3,4-methylenedioxymethamphetamine (MDMA): a review.
    O'Leary G; Nargiso J; Weiss RD
    Curr Psychiatry Rep; 2001 Dec; 3(6):477-83. PubMed ID: 11707161
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Commentary on Halpern et al. (2011): strengthening the case against functionally significant serotonergic neurotoxicity in human MDMA (ecstasy) users.
    Lyvers M
    Addiction; 2011 Apr; 106(4):787-8. PubMed ID: 21371152
    [No Abstract]   [Full Text] [Related]  

  • 35. Ecstasy induced acute hepatic failure. Case reports.
    Atayan Y; Çağın YF; Erdoğan MA; Harputluoglu MM; Bilgic Y
    Acta Gastroenterol Belg; 2015; 78(1):53-5. PubMed ID: 26118578
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-term neuropsychiatric consequences of "ecstasy" (MDMA): a review.
    Montoya AG; Sorrentino R; Lukas SE; Price BH
    Harv Rev Psychiatry; 2002; 10(4):212-20. PubMed ID: 12119307
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The ugly side of amphetamines: short- and long-term toxicity of 3,4-methylenedioxymethamphetamine (MDMA, 'Ecstasy'), methamphetamine and D-amphetamine.
    Steinkellner T; Freissmuth M; Sitte HH; Montgomery T
    Biol Chem; 2011 Jan; 392(1-2):103-15. PubMed ID: 21194370
    [TBL] [Abstract][Full Text] [Related]  

  • 38. 3,4-Methylenedioxymethamphetamine (ecstasy)-induced hepatotoxicity: multidetector CT and pathology findings.
    Lawler LP; Abraham S; Fishman EK
    J Comput Assist Tomogr; 2001; 25(4):649-52. PubMed ID: 11473199
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neurocognitive impairments in MDMA and other drug users: MDMA alone may not be a cognitive risk factor.
    Hanson KL; Luciana M
    J Clin Exp Neuropsychol; 2010 Apr; 32(4):337-49. PubMed ID: 20397296
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Addressing the threats of MDMA (Ecstasy): implications for school health professionals, parents, and community members.
    Wood R; Synovitz LB
    J Sch Health; 2001 Jan; 71(1):38-41. PubMed ID: 11221539
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.